Trials / Unknown
UnknownNCT06010888
Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC
Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC: An Exploratory Clinical Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 92 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to learn about the efficacy and safety of Fruquintinib with mFOLFOX6/FOLFIRI in patients with mCRC. The main question it aims to answer is: The conversion surgery rate of the therapy mentioned above. The ORR, R0 surgery rate, DCR, PFS, OS, and safety will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fruquintinib+mFOLFOX6/FOLFIRI | Fruquintinib: 4mg po qd, d1-d21, q4w with mFOLFOX6/FOLFIRI (standard) |
Timeline
- Start date
- 2023-10-31
- Primary completion
- 2024-10-31
- Completion
- 2026-03-31
- First posted
- 2023-08-25
- Last updated
- 2023-08-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06010888. Inclusion in this directory is not an endorsement.